Business, energy, technology, markets and global industry news from Business News Today

hepatocellular carcinoma

PharmaDeviceNews hepatocellular carcinoma
Confluence Genetics’ Cas-CLEAR CRISPR platform is designed to use cancer-linked RNA mutations as triggers for selective tumor cell destruction, opening a potential new precision oncology pathway. Representative image.
Pharma & Biotech

Could Confluence Genetics’ Cas-CLEAR platform open a new path for liver cancer therapy?

Confluence Genetics launches Cas-CLEAR, a Cas12a2 CRISPR platform designed to kill mutation-bearing cancer cells. Explore the evidence and risks.

Read More
Representative image of liver cancer research and CAR-T therapy development, reflecting growing industry interest in Oricell’s Ori-C101 data for late-line hepatocellular carcinoma.
Pharma & Biotech

Oricell’s ASCO 2026 liver cancer data put GPC3 CAR-T back in the spotlight

Find out how Oricell’s Ori-C101 CAR-T data could reshape expectations for late-line liver cancer treatment after ASCO 2026.

Read More
Pharma & Biotech

Why AstraZeneca’s EMERALD-3 and SERENA-6 data could influence future standards of cancer care

Could AstraZeneca’s latest ASCO 2026 cancer data reshape future treatment sequencing in liver and breast oncology? Read the full analysis.

Read More
Representative image: A clinical researcher reviews liver cancer scan data in an oncology research setting, illustrating the growing focus on Agenus’ botensilimab and balstilimab combination in post-immunotherapy hepatocellular carcinoma treatment.
Pharma & Biotech

Can Agenus turn botensilimab and balstilimab into a serious post-ICI liver cancer contender?

Post-ICI liver cancer has few strong options. Agenus’ BOT plus BAL data raise the next question: can durability survive larger trials?

Read More
Representative image: Advanced liver cancer imaging and RNA-based oncology research illustrate Rznomics Inc.’s FDA RMAT designation for RZ-001 in hepatocellular carcinoma, highlighting the growing role of RNA editing in next-generation cancer therapy.
Pharma & Biotech

FDA RMAT status puts Rznomics’ RNA editing platform under a brighter clinical spotlight

RNA editing just gained a liver cancer spotlight. Rznomics must now prove RZ-001 can turn early response signals into durable clinical value.

Read More
Pharma & Biotech

Can Rznomics turn RZ-001 into a breakthrough therapy for hepatocellular carcinoma?

Rznomics reported interim RZ-001 liver cancer data at AACR 2026. Read why the efficacy and safety signals could matter for hepatocellular carcinoma.

Read More
Pharma & Biotech

Can Abbisko Therapeutics turn irpagratinib into the first approved FGFR4 therapy for hepatocellular carcinoma?

Abbisko Therapeutics won EMA orphan drug designation for irpagratinib in liver cancer. Read what this changes for FGFR4-targeted therapy.

Read More
Pilatus Biosciences moves beyond PD 1 with FDA backed Fast Track pathway for PLT012
Pharma & Biotech

Can targeting CD36 reshape hepatocellular carcinoma immunotherapy? Pilatus Biosciences takes first step

Pilatus Biosciences earns FDA Fast Track for PLT012 in liver cancer. Read why CD36 targeting could reshape immunotherapy development.

Read More
Pharma & Biotech

What AstraZeneca’s C-CAR031 deal reveals about the future of CAR-T in liver cancer

AstraZeneca takes full control of a GPC3 CAR-T therapy for liver cancer. Find out what this deal changes and what risks still loom.

Read More